Last reviewed · How we verify
NCT03767621: iLITRO
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR
trial testing Indication of revascularization in Coronary Artery Disease in 300 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2026
Quick facts
| Lead sponsor | Fundación EPIC |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 19 February 2019 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 38 locations across Spain |
Drugs / interventions tested
- Indication of revascularization
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Left Main Coronary Artery Stenosis — all drugs for Left Main Coronary Artery Stenosis →
- Left Main Coronary Artery Disease — all drugs for Left Main Coronary Artery Disease →
- Restenosis, Coronary — all drugs for Restenosis, Coronary →
Sponsor
Fundación EPIC — full company profile →
Who can join
18 and older, any sex, with Coronary Artery Disease or Left Main Coronary Artery Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The assessment of Left Main Coronary Artery (LMCA) lesions by means of coronary angiography renders serious limitations. Studies with a limited number of patients have shown that a value of FFR (Fractional Flow Reserve) above 0.80 identify a low risk of events in case of not performing revascularization in patients with intermediate stenosis in the LMCA. Although iFR (Instant wave Free Ratio) has recently been found equivalent to FFR The demonstration of the prognostic utility of iFR in patients with LMCA intermediate lesions could have an important clinical impact and justify its systematic use for the treatment decision in these high-risk patients.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Instantaneous Wave-Free Ratio for the Assessment of Intermediate Left Main Coronary Artery Stenosis: Correlations With Fractional Flow Reserve/Intravascular Ultrasound and Prognostic Implications: The iLITRO-EPIC07 Study.
Rodriguez-Leor O, de la Torre Hernández JM, García-Camarero T, García Del Blanco B, et al · · 2022 · cited 17× · PMID 36111801 · DOI 10.1161/circinterventions.122.012328 -
Reliability of Instantaneous Wave-Free Ratio (iFR) for the Evaluation of Left Main Coronary Artery Lesions.
De Rosa S, Polimeni A, De Velli G, Conte M, et al · · 2019 · cited 12× · PMID 31370353 · DOI 10.3390/jcm8081143 -
Contemporary Left Main Percutaneous Coronary Intervention: A State-of-the-art Review.
Showkathali R, Yalamanchi RP. · · 2023 · cited 4× · PMID 37435600 · DOI 10.15420/icr.2023.02 -
Selección de lo mejor del año 2020 en cardiología intervencionista Selection of the best of 2020 in interventional cardiology
Ojeda S, Romaguera R, Cruz-González I, Moreno R. · · 2020
Verify or expand the search:
- PubMed search for NCT03767621
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Fundación EPIC trials
Trials by the same sponsor.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07260474 — Comparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure · NA · not yet recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
- NCT07190690 — Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both · NA · recruiting
- NCT07256249 — Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selutio · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03767621 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación EPIC
- Last refreshed: 5 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03767621.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing